Related Experiment Video

Updated: May 29, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients

Vincent Soriano, Kenneth E Sherman, Juergen Rockstroh

    AIDS (London, England)
    |August 26, 2011
    PubMed

    Insights

    Direct-acting antivirals (DAAs) offer hope for curing chronic hepatitis C in HIV patients. However, off-label use may lead to resistance and toxicity, particularly in resource-poor nations.

    Area of Science:

    • Hepatology
    • Virology
    • Infectious Diseases

    Background:

    • Direct-acting antivirals (DAAs) represent a significant advancement in treating chronic hepatitis C (HCV) infection.
    • Co-infection with human immunodeficiency virus (HIV) accelerates liver disease progression, making HCV treatment crucial.

    Discussion:

    • Judicious use of DAAs can cure many HIV-HCV co-infected patients.
    • Off-label or suboptimal DAA use can result in toxicities, drug interactions, and the selection of drug-resistant HCV variants.
    • First-generation DAAs may disproportionately affect non-genotype 1 or drug-resistant HCV infections.

    Key Insights:

    • HIV-HCV co-infection necessitates effective and safe treatment strategies.
    • The emergence of drug resistance and toxicity are critical concerns with widespread DAA use.
    • Resource-limited settings face challenges in accessing HCV therapy, potentially concentrating difficult-to-treat cases.

    Outlook:

    • Future DAA development should consider resistance profiles and co-infection complexities.
    • Ensuring equitable access to effective HCV treatment in resource-poor nations is paramount.
    • Continued research is needed to optimize DAA regimens for diverse patient populations and HCV genotypes.

    More Related Videos

    Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors16:49

    Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

    Published on: July 16, 2012

    "Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

    "Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

    Published on: February 19, 2019

    Related Concept Videos

    Hepatitis01:25

    Hepatitis

    Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
    Retrovirus Life Cycles01:10

    Retrovirus Life Cycles

    Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
    Viral Hepatitis I: Introduction01:28

    Viral Hepatitis I: Introduction

    Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

    Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
    Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

    Pharmacokinetics: Drug–Food and Drug–Viral Interactions

    A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...